Latest Us Growth News

MedAdvisor Limited has finalized the sale of its Australian and New Zealand operations to Jonas Software for an estimated $42.35 million, marking a strategic pivot towards its US business. The company also announced upcoming CFO changes as it refocuses its growth trajectory.

Cobram Estate Olives has reported a record 2025 Australian olive harvest with a 10.2% increase in production and forecasts a strong FY2025 EBITDA of $115 million. The company also announces strategic moves including a CEO relocation to the US and acquisition of farming machinery business Leda Ag.

QuickFee Limited has successfully completed an oversubscribed Share Purchase Plan, raising a total of A$1.532 million alongside a recent placement, positioning the fintech for accelerated loan book expansion in the US and Australia.

Xero Limited has announced a binding agreement to acquire Melio Limited for US$2.5 billion, backed by a fully underwritten A$1.85 billion equity raise. This strategic move aims to accelerate Xero’s US growth and more than double its FY25 revenue by FY28.

Xero Limited has agreed to acquire Melio Limited, a leading US SMB bill pay platform, for US$2.5 billion, marking a significant leap in its US growth strategy. The deal is backed by a substantial A$1.85 billion equity raise and aims to accelerate revenue and market presence by FY28.

Adherium Limited is raising up to $4 million through a partially underwritten entitlement offer to expand its US digital health platform and recruit key personnel. The capital raise supports scaling patient onboarding and advancing its FDA-cleared smart inhaler technology.

Kelsian’s US subsidiary Hotard Coaches has landed a major contract to provide workforce transportation for the Louisiana LNG development, marking a significant step in its industrial transport expansion.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

Zip Co Limited has raised its FY25 cash EBTDA guidance to at least $160 million, driven by robust transaction growth in the US market exceeding 40% year-on-year in May 2025. The company also continues its share buy-back program amid steady credit performance.

Hydralyte USA reports its best EBITDA performance since IPO, driven by strong sales and cost reductions, setting the stage for growth with upcoming product launches.

Pacific Edge Limited has launched a NZ$20 million capital raise to bolster its cash reserves amid the loss of Medicare coverage for its bladder cancer diagnostic tests, aiming to accelerate US market adoption and support new product development.

PainChek Limited has secured a pivotal reseller and integration deal with Eldermark Software, positioning its AI-driven pain assessment app for a major US market rollout pending FDA approval.